Article
Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer.
Oncotarget - 5 Jul 2016
Pershing Nicole L K, Yang Chi-Fu Jeffrey, Xu MengMeng, Counter Christopher M
Abstract excerpt
Oncogenic mutations in the gene KRAS are commonly detected in non-small cell lung cancer (NSCLC). This disease is inherently difficult to treat, and combinations involving platinum-based drugs remain the therapeutic mainstay. In terms of novel, pharmacologically actionable targets, nitric oxide synthases (NOS) have been implicated in the etiology of KRAS-driven cancers, including lung cancer, and small molecular...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.